製品名:(3R)-oxolan-3-amine

IUPAC Name:(3R)-oxolan-3-amine

CAS番号:111769-26-7
分子式:C4H9NO
純度:97%
カタログ番号:CM104557
分子量:87.12

包装単位 有効在庫 価格(USD) 数量
CM104557-1g in stock Ǡş
CM104557-5g in stock ƅdžœ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:111769-26-7
分子式:C4H9NO
融点:-
SMILESコード:N[C@@H]1CCOC1
密度:
カタログ番号:CM104557
分子量:87.12
沸点:
MDL番号:MFCD08234424
保管方法:

Category Infos

Tetrahydrofurans
Tetrahydrofuran is a heterocyclic organic compound with the molecular formula C4H8O. Tetrahydrofuran belongs to ethers and is the complete hydrogenation product of furan. It is a colorless, water-miscible organic liquid with small viscosity at normal temperature and pressure. Because of its long liquid range, it is a commonly used medium polar aprotic solvent. Its main use is as a precursor of high molecular polymers.

Column Infos

Furans
Furan is a cyclic flammable liquid compound C4H4O that is obtained from wood oils of pines or made synthetically and is used especially in organic synthesis. Furan is aromatic because a pair of lone pair electrons of the oxygen atom in its molecule forms a large π bond in the plane of the conjugated orbital, making a total of 6 electrons in the plane of the conjugated plane, conforming to the 4n+2 structure. Aromaticity makes furan have the property of easy substitution and difficult addition. The other lone pair of electrons in oxygen stretches out. The oxygen atom itself conforms to sp2 hybridization. Due to the presence of the aromatic ring, the chemical behavior of furan is not very similar to that of other unsaturated heterocycles. The oxygen in the aromatic ring has an electron-donating effect, so the electrophilic substitution reactivity of furan is stronger than that of benzene.
CVN424
In a Phase 2 clinical trial, CVN424, a novel, non-dopaminergic, GPR6 inverse agonist, demonstrated a significant reduction in OFF time and was safe and well tolerated with low rates of mostly mild and moderate adverse events. Patients also reported enhanced motor functionality in daily activities, as assessed by the UPDRS Part II. These findings enhance the confidence in CVN424's potential to address both motor and non-motor symptoms of Parkinson’s disease, consistent with observations in pre-clinical models, potentially heralding a transformative non-dopaminergic therapy.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products